MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [31] Ado-trastuzumab emtansine - The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
    Ganguly, Sandip
    Ghosh, Joydeep
    Biswas, Bivas
    Dabkara, Deepak
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (02) : 218 - 220
  • [32] Human epidermal growth factor receptor 2-positive digestive tumors
    Wagner, Anna D.
    Ozdemir, Berna C.
    Rueschoff, Josef
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (04) : 354 - 361
  • [33] The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy
    Lanning, Ryan M.
    Morrow, Monica
    Riaz, Nadeem
    McArthur, Heather L.
    Dang, Chau
    Moo, Tracy-Ann
    El-Tamer, Mahmoud
    Krause, Kate
    Siu, Chun
    Hsu, Meier
    Zhang, Zhigang
    Pei, Xin
    McCormick, Beryl
    Powell, Simon N.
    Ho, Alice
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) : 2517 - 2525
  • [34] The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy
    Ryan M. Lanning
    Monica Morrow
    Nadeem Riaz
    Heather L. McArthur
    Chau Dang
    Tracy-Ann Moo
    Mahmoud El-Tamer
    Kate Krause
    Chun Siu
    Meier Hsu
    Zhigang Zhang
    Xin Pei
    Beryl McCormick
    Simon N. Powell
    Alice Ho
    Annals of Surgical Oncology, 2015, 22 : 2517 - 2525
  • [35] Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Bines, Jose
    Procter, Marion
    Restuccia, Eleonora
    Viale, Giuseppe
    Zardavas, Dimitrios
    Suter, Thomas
    Arahmani, Amal
    Van Dooren, Veerle
    Baselga, Jose
    Clark, Emma
    Eng-Wong, Jennifer
    Gelber, Richard D.
    Piccart, Martine
    Mobus, Volker
    de Azambuja, Evandro
    CLINICAL BREAST CANCER, 2020, 20 (02) : 174 - +
  • [36] The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy
    Gopal, R.
    BREAST DISEASES, 2016, 27 (02): : 160 - 161
  • [37] Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models
    Shu, Sei
    Yamashita-Kashima, Yoriko
    Yanagisawa, Mieko
    Nakanishi, Hayao
    Kodera, Yasuhiro
    Harada, Naoki
    Yoshimura, Yasushi
    ANTI-CANCER DRUGS, 2020, 31 (03) : 241 - 250
  • [38] Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load Reply
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : E357 - E357
  • [39] Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells
    Wang, Hongbin
    Wang, Wenqian
    Xu, Yongping
    Yang, Yong
    Chen, Xiaoyan
    Quan, Haitian
    Lou, Liguang
    CANCER SCIENCE, 2017, 108 (07) : 1458 - 1468
  • [40] Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Cholangiocarcinoma
    Law, Lisa Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : E271 - E273